Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma

Harsha Trivedi, RN, PhD, Blanche Mavromatis, MD, Usha Sree Chamarthy, MD, Anas Al-Janadi, MD, Vicki Gilreath, RN, Gordan Srkalovic, MD, PhD

Blood (2010) 116 (21): 5046.

https://doi.org/10.1182/blood.V116.21.5046.5046

Published: 2010

Journal Articles

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Blanche Mavromatis, MD, Kanti R. Rai, MD, Paul K. Wallace, PhD, Claudia Soho, OCN, Beverly Landrigan, RN, Patricia Meyn, RN, Tracey Wei, MS, Kenneth K. Chan, PhD, Philomena Casey, MS, Steven C. Novick, MD, PhD, Asher A. Chanan-Khan, MD

Blood (2005) 106 (11): 2129.

https://doi.org/10.1182/blood.V106.11.2129.2129

Published: 2005

Journal Articles

A Prognostic Model Using ZAP- 70, CD38 and Cytogenetics To Better Predict Need for Early Therapy and Response to Treatment in Chronic Lymphocytic Leukemia (CLL).

Peter Acs, MD, Blanche Mavromatis, MD, Metin Ozdemirly, MD, Daniel Hartmann, PhD, Jean Meck, PhD, Emre Zafer, MD, Rebecca Slack, Bruce Cheson, MD

Blood (2005) 106 (11): 2114.

https://doi.org/10.1182/blood.V106.11.2114.2114

Published: 2005

Journal Articles

Treatment Outcomes in Patients (Pts) with Transformed Chronic Lymphocytic Leukemia (CLL) in One Institution.

Peter Acs, MD, Blanche Mavromatis, MD, Metin Ozdemirli, MD, Daniel Hartman, PhD, Bruce Cheson, MD

Blood (2005) 106 (11): 5031.

https://doi.org/10.1182/blood.V106.11.5031.5031

Published: 2005

Journal Articles

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Asher Alban Chanan-Khan, MD, Blanche Mavromatis, MD, Kanti R. Rai, MD, Philomena Casey, Steven Novick, MD, Loretta M. Itri, MD

Blood (2004) 104 (11): 4827.

https://doi.org/10.1182/blood.V104.11.4827.4827

Published: 2004

NARROW

Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

A Prognostic Model Using ZAP- 70, CD38 and Cytogenetics To Better Predict Need for Early Therapy and Response to Treatment in Chronic Lymphocytic Leukemia (CLL).

Treatment Outcomes in Patients (Pts) with Transformed Chronic Lymphocytic Leukemia (CLL) in One Institution.

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Four Cycles of Standard Bortezomib and Dexamethasone Produce Significant Overall Response Rates In Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of the Combination of Genasense™ (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

A Prognostic Model Using ZAP- 70, CD38 and Cytogenetics To Better Predict Need for Early Therapy and Response to Treatment in Chronic Lymphocytic Leukemia (CLL).

Treatment Outcomes in Patients (Pts) with Transformed Chronic Lymphocytic Leukemia (CLL) in One Institution.

A Pilot Study of Genasense® (Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated and Untreated Subjects with Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only